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ABSTRACT
Objectives BRIGHTLIGHT is a national evaluation 
of cancer services for teenagers and young adults 
in England. Following challenges with recruitment, 
our aim was to understand more fully healthcare 
professionals’ perspectives of the challenges of 
recruiting young people to a low-risk observational 
study, and to provide guidance for future recruitment 
processes.
Design Qualitative.
Setting National Health Service (NHS) hospitals in 
England.
Methods Semistructured telephone interviews with 
a convenience sample of 23 healthcare professionals. 
Participants included principal investigators/other 
staff recruiting into the BRIGHTLIGHT study. Data were 
analysed using framework analysis.
Results The emergent themes were linked to levels 
of research organisational management, described 
using the levels of social network analysis: micro-level 
(the individual; in this case the target population to 
be recruited—young people with cancer); meso-level 
(the organisation; refers to place of recruitment and 
people responsible for recruitment); and macro-level 
(the large-scale or global structure; refers to the wider 
research function of the NHS and associated policies). 
Study-related issues occurred across all three levels, 
which were influenced by the context of the study. At 
the meso-level, professionals’ perceptions of young 
people and communication between professionals 
generated age/cancer type silos, resulting in 
recruitment of either children or adults, but not both 
by the same team, and only in the cancer type the 
recruiting professional was aligned to. At the macro-
level the main barrier was discordant configuration of a 
research service with a clinical service.
Conclusions This study has identified significant 
barriers to recruitment mainly at the meso-level and 
macro-level, which are more challenging for research 
teams to influence. We suggest that interconnected 
whole-system changes are required to facilitate 
the success of interventions designed to improve 
recruitment. Interventions targeted at study design/
management and the micro-level only may be less 
successful. We offer solutions to be considered by those 
involved at all levels of research for this population.
InTRODuCTIOn
Challenges affecting recruitment to research 
studies in healthcare have been reported 
frequently in the literature1–4 and are often 
regarded as the most demanding phase of 
the research process. Various interventions 
have been used to improve recruitment, 
but few have been shown to be successful.5–7 
What has received less attention is the identi-
fication and understanding of recruitment to 
research in populations often termed ‘hard to 
reach’; this includes people who are socially 
disadvantaged, viewed as vulnerable or 
low-frequency populations.8 One such group 
are teenagers and young adults (TYA) with 
cancer, who have been shown to have lower 
rates of recruitment to clinical trials than chil-
dren and older adults,9 10 a factor that may 
contribute to worse clinical outcomes in this 
population.11 In a recent review of recruit-
ment of young people with cancer to clinical 
trials, Fern et al10 identified five key issues to be 
addressed to optimise recruitment: awareness, 
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Research
Strengths and limitations of this study
 ► This study highlights that barriers to recruitment 
occur across multiple levels identified through in-
depth interviews with healthcare professionals 
working in National Health Service (NHS) research 
across England.
 ► Participants were recruited from the complete 
range of hospital environments where young 
people are cared for in the NHS, including oncology, 
haematology, adult, child and specialist teenage and 
young adult cancer units.
 ► Barriers to recruitment for teenagers and young 
adults were examined, although the results may be 
transferable to other research in rare cancers.
 ► This study explored the barriers to recruitment to a 
low-risk observational study, and there maybe wider 
issues in more complex studies of all designs.
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Figure 1 Summary of the process of recruiting to 
BRIGHTLIGHT. 1Recruiting until the day before the 25th 
birthday so this ensured we captured those diagnosed at 
24.99 years but started treatment aged 25. 2This was a drop-
down menu with several options: ‘Excluded (please specify), 
recruited, refused [+/-agree to contact details being retained], 
referred to another hospital, no longer treated at this hospital, 
no contact with the hospital this month, other (please 
specify)’. CWT, Cancer Wait Time data set; NWKIT, North 
West Knowledge Intelligence Team—the cancer registry 
responsible for TYA data; TYA, teenagers and young adults.
availability, appropriateness, access and acceptability; this 
conceptual model was applied during the development 
and set-up of the BRIGHTLIGHT cohort study, a national 
evaluation of TYA cancer services in England.12 
BRIGHTLIGHT cohort study in the context of recruitment to 
cancer clinical trials in England
In England research fulfilling specific criteria is eligible 
to be included in the National Institute for Health 
Research (NIHR) portfolio of studies (http://www. 
nihr. ac. uk/ research- and- impact/ nihr- clinical- research- 
network- portfolio/, accessed 21 March 2017). Portfolio 
acceptance means the study is then eligible for support 
by healthcare professionals employed by the Clinical 
Research Network (CRN). This support includes study 
set-up and management. The CRN in England is divided 
into 15 networks supporting research in 30 clinical 
specialities (http://www. nihr. ac. uk/ about- us/ how- we- 
are- managed/ managing- centres/ crn/ our- structure. htm, 
accessed 21 March 2017), including cancer (the cancer 
network was reduced to 15 from 32 local networks in 
2014). This network facilitates recruitment to research 
across the country by employing researchers (nurses, trial 
practitioners, data managers). The principal aim of the 
CRN is to increase accrual into clinical trials. However, it 
also supports other types of studies providing eligibility 
criteria for portfolio inclusion are fulfilled.
BRIGHTLIGHT is a cohort study involving young 
people with a primary cancer diagnosis made between the 
ages of 13 and 24 years. Data were collected from young 
people through a bespoke survey13 administered at 5–7, 
12, 18, 24 and 36 months after diagnosis by an indepen-
dent research company. Within the clinical setting health-
care professionals sought consent from young people to 
be contacted by the research company for data collection. 
Specialist cancer care for young people is provided by 
13 principal treatment centres (PTC); however, approx-
imately 50% of young people receive care outside of a 
PTC.14 In order to offer study participation to all young 
people, it was necessary to open the study to recruitment 
in as many hospitals in England as possible. Young people 
present with a spectrum of cancer types11 and are likely 
to attend various clinics within one hospital; thus, two 
challenges to recruitment were evident at the outset: (1) 
identifying young people who were potentially eligible 
for BRIGHTLIGHT; and (2) gaining their consent. The 
first challenge was overcome by using routinely collected 
National Health Service (NHS) data. The Cancer Waits 
data set records the details of all suspected cancer cases 
followed by the date of first treatment. While it is primarily 
designed to monitor government targets, used in real time 
(rather than after the end of year checks for accuracy) 
it was possible to identify young people within 3 months 
of diagnosis. This allowed the potential for recruitment 
of young people and data collection for the first survey 
within 5–7 months of diagnosis. The second challenge 
was overcome using the cancer registry which could 
distribute a list of patient names for each participating 
hospital to a designated member of the CRN based 
there, allowing a researcher working with the relevant 
cancer type to approach and recruit young people in that 
hospital (figure 1). The healthcare professional respon-
sible for recruiting young people to BRIGHTLIGHT was 
hospital-dependent and ranged from a clinical trial assis-
tant to the lead clinician for TYA.
Prior feasibility work of this mechanism suggested we 
could recruit our target sample of 2012 young people in 
18 months.15 However, our recruitment period needed to 
be extended by an additional 12 months with a reduced 
final sample of 1114 young people. Throughout the 
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recruitment period, we implemented several changes to 
improve recruitment, none of which were successful.16
Studies in which healthcare professionals reflect on the 
research process have identified several factors perceived 
to impact on recruitment. These include bureaucratic 
delays in the NHS research and development approval 
process17 18; inadequate research infrastructure; percep-
tion of certain clinical trials being harder to recruit to; 
influence of the characteristics of those recruiting and 
those participating, which may mean some patients are 
not approached to participate19; competition for research 
participants; tension between clinical practice and clinical 
research workload; staff perception of patient benefit and 
burden; and the low status given to recruitment skills.1 
These reasons are often taken and accepted at face value 
and are perpetuated across studies rather than being 
challenged and interrogated to look for structural-level 
and individual-level solutions to minimise their negative 
impact on recruitment.
Aims
1. To gather detailed understanding of the challenges 
to recruiting young people to BRIGHTLIGHT from 
the perspective of healthcare professionals involved in 
recruitment.
2. To provide guidance to optimise recruitment of young 
people to research in the future.
METHODS
Study design
This was a qualitative study involving healthcare profes-
sionals involved in recruitment to the BRIGHTLIGHT 
cohort study as either principal investigators (PIs) or in 
other research roles.
Participants and setting
BRIGHTLIGHT was open to recruitment from 
September 2012 to April 2015 in 109 NHS hospitals 
in England. At the end of recruitment healthcare 
professionals (between 2 and 12 in each hospital) 
were requested to complete an End of Recruitment 
Questionnaire (EoRQ), with PIs asked to encourage 
at least one response per hospital.16 The EoRQ 
included the option to participate in a telephone 
interview to further explore the recruitment expe-
rience from the healthcare professionals’ perspec-
tive. Healthcare professionals who provided their 
contact details were sent an email by an experienced 
social science researcher (CK) independent from 
the BRIGHTLIGHT team, in which they were given a 
brief overview of the purpose and length of the inter-
view (approximately 30 min). They were provided 
with a range of times/dates for the interview or could 
suggest alternative times/dates to enable flexibility 
around participation. Participation in the interview 
was taken as consent. Healthcare professionals could 
stop the interview at any time without specifying a 
reason. They were assured that their identity would 
remain confidential and not revealed to the BRIGHT-
LIGHT team.
Data collection
Data were collected through semistructured telephone 
interviews between July and August 2015, while recall 
of recruitment to BRIGHTLIGHT was still recent. The 
interview schedule was based on the EoRQ and estab-
lished the role and involvement of the healthcare profes-
sionals in BRIGHTLIGHT, their research experience, 
preparedness for recruiting to BRIGHTLIGHT, and their 
approach to recruitment as well as the context for recruit-
ment within their hospital, for example, involvement of 
research and clinical teams (see online supplementary 
file 1 for the results of the EoRQ). The interview also 
explored optimal recruitment mechanisms and partic-
ularly why this was not achieved, concluding with the 
interviewee’s overall reflection on the BRIGHTLIGHT 
study. At the end of the interview healthcare profes-
sionals were given the opportunity of adding any further 
comments. Additional probing ensured that responses 
could be further explored and clarified. For example, if 
specific reasons for not recruiting young people outside 
the eligibility criteria were reported, probes were used 
to understand the thought processes underpinning this 
decision and whether this was informed by communi-
cation with the BRIGHTLIGHT research team or was a 
local or individual interpretation of inclusion or exclu-
sion criteria. With permission, all interviews were digi-
tally recorded and transcribed verbatim.
Analysis
The interview data were analysed using framework 
analysis.20 21 This is a pragmatic approach that permits 
theme-based or case-based analysis and collaborative 
team analysis. It permits a structured and rigorous 
process for managing data, and provides transparency 
and an audit trail during analysis, and conclusions to be 
checked against the original data. The transcripts were 
anonymised (including all references to the hospitals 
involved) and divided between six members of the 
BRIGHTLIGHT team who each received three or four 
transcripts. They familiarised themselves with the tran-
scripts and independently indexed and charted data 
summarising data per participant and theme based on 
a framework developed and piloted by two researchers 
(CK, RMT), both of whom had read all the transcripts. 
When complete, the charts were collated and collec-
tively the research team met to discuss the charted 
data to identify key subthemes within each broad 
framework theme, enabling the data to be reduced 
into categories. The categories were refined through 
further discussion and checked against the original 
transcripts. Finally, another researcher (FG) reviewed 
the analysis to ensure interpretation remained true to 
the transcripts as a way of ensuring there was no bias 
(as the BRIGHTLIGHT team had been integral to the 
analysis).
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Table 1 Participant characteristics
Characteristics n %
Professional background
  Research nurse—adult 15 66
  Research nurse—paediatric 3 13
  Clinical nurse—TYA 3 13
  Other 2 8
Type of hospital
  TYA principal treatment centre 5 22
  TYA designated hospital 14 61
  Other cancer unit 4 17
Role in BRIGHTLIGHT
  Principal investigator 12 52
  Recruitment role 11 48
TYA, teenage and young adult. Figure 2 Challenges to recruitment by the level they 
occur. NIHR CRN, National Institute for Health Clinical 
Research Network; TYA, teenage and young adult.
RESuLTS
Forty-three healthcare professionals indicated they 
were willing to participate in an interview, of whom 
36 provided contact details and 23 (64%) participated 
(table 1).
Emerging themes reflected the level within the 
English research network that the challenge arose; 
these are presented according to social network 
theory. A social network is defined as ‘any bounded 
set of connected social units’ and are characterised 
by boundaries between networks, being embedded 
in a larger social system and having links between 
members.22 Used here, theory-guided presentation of 
findings was relevant to make the most of the concept 
‘network’ and the relationship between its constituent 
parts. The overarching themes are described using 
the levels of social network analysis23–25: micro (the 
individual), meso (the organisation) and macro (the 
large-scale or global network). This approach to the 
presentation of the findings has enabled subthemes 
to be described within the hierarchy of healthcare 
research in England:
1. Micro-level: refers to the target population to be 
recruited (eg, young people).
2. Meso-level: refers to the place where recruitment was 
occurring and the persons responsible for recruit-
ment.
3. Macro-level: refers to the wider research/NHS 
structure and policies.
Study-related issues to the recruitment challenges 
occurred across the three levels and either influ-
enced or were influenced by the context of the study 
(figure 2). These are presented first in our findings. We 
include relevant and occasionally long quotes, as well as 
probing questions used, where we thought it necessary 
to be expansive when emphasising a point.
STuDy-RELATED fACTORS
Before outlining the issues related to recruitment 
according to the three system levels, it is necessary to 
provide the context of healthcare professionals’ percep-
tions of the study. This refers to the design of a specific 
research project, the study coordinating team who are 
responsible for overseeing and managing the study 
including compliance with ethics, liaising with the sponsor 
and recruiting hospitals, and overall coordination of 
the study. In this paper, it refers to BRIGHTLIGHT and 
the BRIGHTLIGHT team primarily based at University 
College London Hospitals NHS Foundation Trust.
Retrospectively healthcare professionals provided 
critiques and affirmative reflections on recruitment to 
BRIGHTLIGHT. One critique related to how healthcare 
professionals were informed of newly diagnosed young 
people through the monthly notification from the cancer 
registry. It was found that these did not identify young 
people in a timely manner despite the findings from the 
feasibility work.15 Consequently, young people were not 
recruited into the study because healthcare professionals 
became aware of them outside the recruitment window.
Then we were told [by the Network] that we didn’t 
need to do any screening and that we would be 
informed in time by those that had picked up patients 
from the cancer registry and we would be informed 
of those patients so we didn’t have to do any in-house 
screening and that didn’t work. By the time we got 
the list from the cancer registry…for the patients it 
was beyond the four months, therefore we missed the 
patients so that’s why we failed to recruit any patients 
and that was really frustrating.
There was a period when the registry stopped sending 
the notification files because of changes in Public 
Health England organisational infrastructure, and this 
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was perceived by some healthcare professionals to have 
severely impacted on recruitment. However, the notifi-
cation file was only suspended for 3 months, and by this 
time (April 2014) most young people were being identi-
fied and recruited independently of the notification list.
Overall healthcare professionals reported that they 
regarded BRIGHTLIGHT as a straightforward obser-
vational study of importance and relevance to the TYA 
patient population:
Well, TYA is quite underrepresented in research so it’s 
quite a good thing, the fact that it was observational, 
from our point of view it was quite easy to conduct, 
so we were more than happy to take part. I mean, we 
don’t do that many TYA people but it’s worth them 
being part of the research.
The PIs and others recruiting to the study were positive 
about the BRIGHTLIGHT team who oversaw and coordi-
nated the study on a day-to-day basis, maintained engage-
ment with each team throughout recruitment and were 
responsive to all their queries about the study:
I think there was very good, clear communication, we 
obviously kept up to date. I think the facilities on line, 
there was lots really, it was fairly well organised. I can’t 
say that anything, if I had any concerns, you know, 
[Senior Research Manager], they were very good, I’d 
only just pick up the phone or something. If I wasn’t 
sure about something in particular, then they’d put 
me on the right lines.
MICRO-LEvEL
The micro-level refers to the individual, in this instance 
the target population to be recruited to a study. For 
BRIGHTLIGHT this related to issues specifically asso-
ciated with the population being recruited. Healthcare 
professionals shared in interviews their reflections of 
young people that influenced recruitment.
We had previously identified from analysis of screening 
logs that young people were not being approached about 
the study.16 The interviews with healthcare professionals 
identified some reasons for this and generally felt they 
had approached all eligible patients presenting in their 
hospital. Healthcare professionals viewed BRIGHT-
LIGHT as being a less burdensome study in contrast to 
interventional clinical trials that may involve multiple 
hospital visits. With BRIGHTLIGHT, after gaining 
consent, young people’s participation was via surveys 
administered face-to-face, by telephone and online by 
an independent research company. They suggested that 
most young people wanted to have the opportunity to be 
involved in studies and use their experiences to contribute 
to improving services. For young people who did not want 
to participate, this was attributed to them not being both-
ered, time required to take part, and being negatively or 
positively influenced by peers in hospital:
I think they [TYA patients] couldn’t be bothered 
a little bit [with data collection]. Maybe not to feel 
well enough. The length, I think the conversations 
on the telephone were quite lengthy [completing a 
questionnaire]. You know yourself if you don’t want 
to talk to someone. I knew you were going to ring me 
today, but, you know, when someone is going to call 
you, you just think not right now. I think that was the 
problem. Then it used to filter through quite quickly 
to the unit. So, the young people would sit together 
and say, “Oh, they ring on this time,” or, “They keep 
ringing and it’s a lengthy procedure,” but since 
obviously we’re not recruiting anyone else, I haven’t 
heard any more from them, from what the patients’ 
opinions are.
What sort of things were they saying to each other?
Just that it was timely, lengthy chats. That they 
knew what the, with you know, if a certain number 
continued to ring repeatedly they’d choose to ignore 
it.
MESO-LEvEL
The meso-level refers to the organisation, in this instance 
the places where individuals were being recruited to the 
research. For BRIGHTLIGHT this related to the hospi-
tals that opened to recruitment and researchers who were 
responsible for identifying, approaching and recruiting 
young people. There were two aspects related to health-
care professionals within these various organisations that 
impacted on recruitment: patient recruitment interac-
tions and communication recruitment practices.
Patient recruitment interactions
Healthcare professionals’ perceptions of young people 
and their experience of recruiting this population to 
healthcare research varied. It was notable that aside 
from four TYA-specific healthcare professionals (three 
TYA clinical nurses and a medical consultant) the age 
specialism—adult or child—of the remaining healthcare 
professionals usually limited the age of patients they iden-
tified and approached for the study:
So, it’s kind of, for me, being an adult [Research 
Nurse] and the thought of dealing with, you 
know, these thirteen-year-old people with a cancer 
diagnosis was absolutely terrifying because I’d not 
worked with children of the-, I’ve only done a bit 
during my training and, you know, chose to work 
with adults because children are very terrifying 
and so the thought of then dealing with all of the 
issues that goes with a teenage cancer diagnosis, I 
actually found that very, very worrying. It was the 
recruitment process. They had talked to them. 
How do I consent them? It was then booking myself 
and the other research nurse onto paediatric GCP 
because we didn’t even understand the difference 
between assent and consent and it was how difficult 
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was that going to be? Thankfully, everybody that we 
came across, within the Trust [hospital], who did 
enter the study, were actually within the adult age 
group. So, it wasn’t the issue that I first thought 
it was going to be, but it potentially could have 
been, you know, if we’d had people [paediatric 
TYA patients] who were remaining within the Trust 
[hospital].
In some sites, it appeared that an age-specific group of 
TYA patients either child or adult were never given the 
opportunity to participate in BRIGHTLIGHT with conse-
quences for the overall study recruitment figures. It was 
also noted in eight transcripts that healthcare profes-
sionals who worked with adults referred to the TYA popu-
lation as children, despite most of this population coming 
under adult care in other clinical settings. The ‘TYA’ label 
therefore seemed to impede recruitment. Additionally, 
screening and approaching patients were perceived to be 
a one-off opportunity, and if the young person was missed 
for example, not in the clinical area when the healthcare 
professional went to see them, then another attempt to 
inform them about the study and recruit may not have 
occurred.
In addition to age, some healthcare professionals also 
described an additional barrier of a desire to protect 
young people. Young people were perceived to need some 
form of protection due to the multiple ‘assumed’ vulnera-
bilities constructed around their age, diagnosis and treat-
ment. This served to reinforce the view that young people 
were a challenge to engage within healthcare and there-
fore in research too. Despite their experience and knowl-
edge of cancer, healthcare professionals emphasised the 
‘cancer identity’ as a continual rather than periodic state 
of vulnerability as a reason not to approach some young 
people about BRIGHTLIGHT during the 4-month recruit-
ment window from diagnosis. The perception of young 
people being too ill to approach about BRIGHTLIGHT 
did not necessarily apply to other research studies, such 
as drug trials requiring the processing of more complex 
information:
I mean, nobody’s [clinical staff] verbalised any 
concerns about the study, but obviously people 
didn’t value the study enough. I know, I recruit to 
randomized controlled trials and tox[icity] studies 
and I don’t have the same issues I’ve had with 
BRIGHTLIGHT.
Healthcare professionals’ interviews revealed a gap 
between the principle of conducting an observational 
study perceived to be straightforward and with broad 
inclusion criteria and the practice of identifying and 
recruiting the relevant population. Healthcare profes-
sionals who had experience in approaching young 
people to research reported positively and recruited well. 
However, some perceived it to be difficult particularly 
among ‘adult’ healthcare professionals, who rarely had 
contact with adolescent or young adult patients due to a 
low prevalence of cancer in this age group in their area of 
clinical expertise:
… as somebody who is an adult nurse. The patient I 
had was obviously about 24, so it was fine, it wouldn’t 
have bothered me, but thinking about a fourteen or 
a fifteen-year-old, that probably would have been a 
little bit more difficult.
Based on the responses of some healthcare profes-
sionals, it appeared, at times, those identifying and 
recruiting patients interpreted the inclusion/exclusion 
criteria beyond what was stipulated in the protocol; for 
example, there was no exclusion of patients receiving 
palliative care (exclude if not anticipated as being alive 
5–7 months after diagnosis), but healthcare professionals 
reported assuming that if a patient was unlikely to be alive 
to complete all waves of data collection via questionnaire 
(3 years of participation), they were not eligible for the 
study. It is unlikely such interpretations would be made 
in clinical trials.
Communications and recruitment practices
Issues were identified relating to communication within 
hospitals. During study set-up the Site Readiness Ques-
tionnaire obtained information on how BRIGHTLIGHT 
would be implemented locally and no significant chal-
lenges were identified.16 Healthcare professionals 
reported mechanisms they had identified to link to 
multidisciplinary team (MDT) coordinators and clinical 
teams to identify young people. However, in practice this 
proved to be more complicated than anticipated. The 
interviews revealed disparity between the way commu-
nication mechanisms were perceived to work within the 
clinical area and their reality. While some healthcare 
professionals reported a link between child/adult cancer 
services, many had not used this link so recruited solely 
to the ‘age-silo’—child or adult—that they worked in 
rather than allow flexibility to accommodate the TYA 
(13–24 years old) research age range. Furthermore, in 
some hospitals recruitment was hindered by ‘cancer-type 
silos’ in addition to ‘age-silos’. Where BRIGHTLIGHT 
recruitment was designated to a healthcare professional 
working within a specific cancer type, recruitment was 
inhibited either due to the increased work burden or 
not recruiting patients with cancers outside their cancer 
type. This was the first realisation of BRIGHTLIGHT that 
mechanisms professionals had proposed to overcome 
the age and/or cancer silos were not a reality so some 
healthcare professionals stuck rigidly to their professional 
clinical boundaries rather than allow flexibility to accom-
modate the TYA (13–24 years old) research age range. 
This affected recruitment of the TYA population, which is 
cross-cutting age and cancer type:
So, is there anybody at your site recruiting the, I 
guess, 17 to 24 year olds?
No, there isn’t, or hasn’t been, sorry.
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So, none of those would’ve been identified at your 
Trust [hospital]?
Well, you see, they have, some of ours don’t transition 
until they’re about eighteen, nineteen, but nothing, 
no none of the older ones. Which is such a shame, 
because I’m sure, you know, there was so many of the, 
you know, testicular cancers and that, that in younger 
adults, cancers should really have, but that was, kind 
of, outside of my remit.
The second communication issue related to staff 
turnover. Healthcare professionals who began 
recruitment to BRIGHTLIGHT did not always 
remain throughout the recruitment period. Prior to 
opening, hospitals needed to attend a site initiation 
visit or confirm they had watched the site initiation 
CD-ROM. After opening to recruitment there were no 
requests for additional site initiation visits nor were 
any requests received for the site initiation CD-ROM; 
when the BRIGHTLIGHT office was sent updated 
delegation logs, the assumption was that the new 
researcher assigned to recruit to BRIGHTLIGHT had 
also viewed the CD-ROM. However, healthcare profes-
sionals assigned to recruit to BRIGHTLIGHT after it 
had opened reported not knowing about the CD-ROM 
and relied on internal handover, which may have been 
a face-to-face meeting or reading the study site file. 
The communication pattern during transition of new 
staff also highlighted misunderstandings of the role of 
PI for those who had taken on the role, especially the 
responsibility they now had for ensuring successful 
recruitment.
Finally, recruitment was disadvantaged because 
there was no mechanism established either by 
BRIGHTLIGHT, the CRN or those recruiting at 
different hospitals to track whether patients were 
approached as their care moved between hospitals. 
For example, healthcare professionals especially from 
non-specialist hospitals reported that if young people 
were transferred soon after diagnosis to a specialist 
TYA unit, they hoped or assumed recruitment would 
occur in the specialist unit, but there was no estab-
lished local mechanism to alert the receiving team of 
the eligibility of a young person or to check if they had 
been approached for the study or indeed recruited. 
Recognition of study accrual by the CRN is based on 
the organisation that recruits the patient so there was 
no incentive for healthcare professionals to contact 
referral hospitals to ensure the young person had 
been approached:
There were some that we did miss for various reasons. 
One of the main reasons, I think, that we missed some 
people is if they were transferred to another hospital 
for treatment. So, by the time I realised, or by the 
time the time was appropriate to speak to them, they 
had been referred to another hospital. So, that was 
the biggest reason.
MACRO-LEvEL
The macro-level refers to the large-scale or global network, 
in this instance the way the NHS culture and configura-
tion of services impacts on recruitment; for BRIGHT-
LIGHT it also related to the function of the CRN.
Clinical cancer services were based on a traditional 
two-population model (child/adult) until the introduc-
tion of the ‘Improving Outcomes Guidance’ in 2005,26 
when there was the more formal acknowledgement of 
a third population: TYA (although some hospitals had 
introduced this model earlier). Since this time, it became 
evident that although TYA cancer care was recognised 
by commissioners for clinical services, this has not been 
replicated within the CRN, so research teams were still 
either focused on children or adults. Furthermore, adult 
research teams were assigned to a specific cancer type, 
rarely cross-cutting, so they would not capture the diverse 
cancer types young people present with (a factor making 
this population so unique10). It became evident within 
the interviews that creating a model of care that encom-
passes the three populations requires both a TYA-specific 
clinical team and a TYA-specific research team:
So most of our research department, and most of 
NHS research, is set up in terms of oncology, people 
with breast cancer, lung cancer, colon cancer and so 
forth. So it’s, kind of, tumour site specific and the 
whole cancer service is based around being some 
specialist, you know, specific research department. 
You’ve got nurses who work on neurology studies, or 
breast studies, or lung studies and it was a completely 
different mind shift when you start looking at age 
rather than tumour site specific.
The culture within cancer services in the NHS emerged 
as a barrier to recruitment. Recruitment to research and 
even screening was presented as being a role for the 
research team, and where there was no research support, 
recruitment suffered:
Then you’re in a situation where, okay, how do we 
recruit these patients? Because they’re in so many 
clinics. You can’t have one researcher running around 
all the clinics to recruit them, even though they are 
not so common. We don’t have TYA researchers, so 
we don’t have a TYA research department, so they’ve 
got research assistants doing neurology and breast 
and so forth and none doing TYA. Trying to ask these 
assistants to get involved was extremely difficult and 
eventually we failed…the recruitment was reliant 
on TYA nurses and doctors to do that. I tell you, as 
doctors, we can’t go to everything because you’ve got 
your own clinic and your own work to manage. So, 
although you concentrate on those patients, which 
are a small proportion that come to your clinic, you 
cannot completely cover different clinics. Again, it 
has been extremely difficult to get other consultants 
to think, “I will keep that in mind.” We tried to 
recruit those patients because, again, we’ve got 30 
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consultants and how many of them do you chase 
around?
Furthermore, there was a culture of viewing research 
according to a hierarchy in terms of clinical trial versus 
observational studies, with the latter having a lower 
priority for receiving attention. It was often deemed inap-
propriate to approach young people to participate in a 
low risk observation study as staff viewed this as burden-
some and of little direct or immediate benefit to young 
people, although there may be less hesitancy approaching 
the same group of young people about participating in a 
clinical trial.
Finally, the CRN supports research in patients from 
cradle to grave, yet as noted previously the current subdi-
vision of child–adult care created ‘age-silos’. It became 
evident that some hospitals had been pressurised to 
open BRIGHTLIGHT as TYA were a priority group for 
the National Cancer Research Institute. However, appro-
priate resources were not allocated to facilitate this. Even 
in specialist TYA units, where there were well-established 
clinical teams and large numbers of patients accessing the 
service, no resource was allocated to research this popu-
lation by the local CRN. It was apparent that, although 
funding and resources should have been available to 
support recruitment to BRIGHTLIGHT, this did not play 
out in practice with resources being allocated elsewhere:
Yes. I suppose the challenge for me was that although 
we’re a big centre, we have very limited staff so I am 
the TYA nurse body for that. I don’t have a CNS. I 
don’t have a research nurse. So, it’s me and a TYA 
support worker. So, those two roles for 30 to 50 
patients a year designated for the teenagers and 
young adults. That was my big challenge. It was just 
me. Yes. Although our research nurses did turn up…
they were strapped…so pharma came first, I’m afraid.
DISCuSSIOn
The aim of this study was to understand the challenges 
encountered by healthcare professionals responsible for 
the recruitment of young people to a national, low-risk, 
observational study. Many of the recruitment issues have 
been reported previously, such as bureaucratic delays,18 
influence of professional attitudes of those recruiting 
and participant demographics,19 or notions of benefit 
or burden to participants.1 However, to our knowledge, 
this is the first time these issues have been discussed in 
relation to the level of study management and the social 
networks in which they occurred; this is important as 
interventions designed to improve recruitment need to 
be appropriately targeted and mindful of the context.
As with other studies,7 we implemented interventions 
to improve recruitment targeted predominantly on the 
study management and population (micro-level), none 
of which had a clearly demonstrable impact on recruit-
ment.16 This study has identified that the significant 
barriers to recruitment tended to be at the meso-level 
and macro-level, where we had limited or no influ-
ence. Without holistic and interconnected changes, it is 
unlikely that interventions to improve recruitment solely 
targeted at study design/management and micro-levels 
will be successful. This holistic approach to recruitment 
requires the recognition that all levels are interconnected 
and need to work together to ensure equilibrium between 
micro-level, meso-level and macro-level.
We have found that within the context of this study, 
an ongoing face-to-face monitoring procedure would be 
beneficial, similar to those used in commercial clinical 
trials, with a clear purpose to check the running and prog-
ress of the study at each site. This would have provided an 
opportunity to update staff new to the study and increase 
‘buy-in’ from healthcare professionals at each site, as 
well as enable feedback about local recruitment issues 
(which may be shared across multiple sites). It would also 
have provided opportunities for the main study team to 
develop solutions and ensure these were implemented via 
follow-up communication, also aiding the meso-level.
The micro-level issues associated with recruitment 
to a study and young people deciding to participate 
or not were not the focus of this study. Reasons young 
people do and do not take part in research have been 
reported elsewhere.27 However, it is important that where 
a young person is eligible to participate in a study, they 
are provided with the relevant information to make this 
choice.12 16 The micro-level and meso-level interconnect 
when healthcare professionals approach young people in 
the TYA age range (13–24). Young people are perceived 
to be hard to recruit to research10 and healthcare profes-
sionals reported difficulties in approaching this group, 
which appear to be due to a lack of confidence or experi-
ence particularly those working with adults. The perceived 
vulnerability (clinical, physical, social, emotional, finan-
cial) of the patient, particularly those who are children 
(under 18 years of age), may act as a deterrent or lead 
to the reticence of healthcare professionals to approach 
them to participate in research. However, ‘vulnerability’ 
is a fluid rather than constant state, so while a patient may 
not be approached at one point in time they could be 
at another time point—later on the same day, week or 
postintervention, for example, chemotherapy.
A key responsibility of a research ethics committee is to 
address issues of benefit and risk for a study population 
and to consider these in relation to the proposed study.28 
This ensures that populations that might be regarded as 
vulnerable, such as young people with cancer, may be 
safely included within research studies. If populations, 
who due to their age or other factors, are excluded 
because they are ‘vulnerable’, then it may impact on the 
generalisability of research results. There are increasing 
expectations of research funders that patients as stake-
holders are involved in all stages of research. The influ-
ence of their insights on a study should be made explicit 
to recruiting staff so that they better understand the 
priorities and perceptions of the study population.28–30 
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This may assist in challenging and overcoming profes-
sional preconceptions which may otherwise adversely 
affect study conduct. There may be another issue worthy 
of further investigation in that healthcare professionals 
may exhibit unconscious bias when designing research 
and recruiting to studies. If clinical research leaders have 
a poor experience of TYA patients adhering to treatment 
plans, for example, turning up for appointments, taking 
medication and so on, a general perception may arise that 
this population will be less likely to engage with research, 
thus potentially hampering future research focused on 
the population.
Learning from and applying some of the operational 
processes of interventional clinical trials, such as moni-
toring visits, may, by providing a greater level of formal 
contact, enhance site performance. Significant time had 
been invested into identifying potential recruitment prob-
lems with the main BRIGHTLIGHT team developing 
mechanisms within the study design for sites to enact 
prior to and during recruitment, yet quantitative evidence 
from the screening logs and recruitment figures16 and 
the qualitative data reported here suggest that recruit-
ment problems associated with the population (micro-
level) remained. However, the most substantial barrier 
to recruitment was at the meso-level, with healthcare 
professionals constructing the TYA population as ‘hard to 
reach’ and difficult to recruit. Healthcare professionals 
perceived young people’s ‘illness’ as a barrier, there was a 
lack of communication between hospitals when patients 
were referred elsewhere, and in some hospitals only 
specific healthcare professionals could consent patients. 
Our attempts to use the expertise of youth support coor-
dinators and social workers, who the BRIGHTLIGHT user 
group felt were best suited to recruiting to this type of 
study,12 were thwarted by hospital research departments 
only allowing doctors and nurses to obtain consent.
These issues appeared to be universal, rather than 
sporadically related to individual hospitals, type of hospital 
or type of professional who was recruiting. Importantly 
recruitment at PTCs who provided specialist care for 
young people was not any better than non-specialist TYA 
Trusts.16 A possible reason for this may be the difference 
in service configuration with clinical services based on 
the three-population model (child, TYA, adult), whereas 
the research services generally remain child–adult. This 
perpetuates the age/cancer type silo that emerged in the 
current study, which impacted on BRIGHTLIGHT and 
could also be an important contributing factor to the 
decline in recruitment of those aged 15–24 to clinical 
trials.31
We found that there was no communication between 
hospitals when young people were transferred for 
specialist care. It could be envisaged that this could 
also occur for cancer types where treatment is complex 
requiring patients to attend more than one hospital. It 
might be worth developing a way for shared accrual to 
recognise that one site may identify a participant, but 
as their care is transferred consent is taken at another 
hospital. This may encourage interhospital communica-
tion and cooperation as there would be a shared benefit 
(accrual) and it may lead to a great number of eligible 
patients being approached for research.
Several suggestions have been proposed previously for 
macro-level interventions, such as sanctions imposed on 
hospitals or PIs when recruitment targets are not met32 
and financial remuneration based on criteria other than 
study accrual.1 In addition, greater parity between how 
healthcare professionals view observational studies, which 
are often regarded as the poor relation to clinical trials, 
needs to be realised.33–35 This could be supported at 
macro-level through driving a change in Good Clinical 
Practice (GCP) training to reflect study designs beyond 
clinical trials and include training on consenting young 
adults. In turn this would also increase parity between 
clinical and observational studies, the range of methods 
for data collection, and their value in contributing to 
improved patient outcomes.
The networks were primarily set up to recruit to 
clinical trials in which they have been successful.36 As 
5-year survival rates for many cancers reach into 80% 
and 90%, and with an increasing focus on patient-re-
ported outcome measures, researchers and subsequently 
the networks must respond to an increasing need for 
research studies that are more observational in nature. 
No hierarchy associated with study design should exist 
as ultimately the goal is to improve overall outcomes for 
patients with cancer whether this be survival or quality 
of life. Our previous work with young people showed 
approximately three-quarters rated survival and quality of 
life as equally important.37
This study had several limitations. The interviewees were 
self-selected, so their subjective views and experiences are 
not necessarily representative of all those recruiting in 
their hospitals. However, the congruence of recruitment 
experiences across hospitals suggests that these were not 
one-off or hospital-specific issues. While saturation was 
reached on the issues raised by those who participated, a 
larger sample would have given us greater certainty that 
we could identify all the key issues. We did not report the 
experiences of young people being recruited to BRIGHT-
LIGHT or the experiences/perspectives of directors and 
senior managers in the CRNs of recruiting to a low-risk, 
cross-cutting age/cancer-type study. Despite these limita-
tions this study indicates what needs to occur at different 
levels of research engagement for recruitment of young 
people with cancer to research (figure 3).
At the end of recruitment to BRIGHTLIGHT, it was 
clear that not all those eligible between 13–24 years and 
diagnosed during the time the study was open were given 
the opportunity to decide to participate. The ‘Improving 
Outcomes Guidance’26 specified young people should 
have access to clinical trials, and PTCs’ coordination of 
care needs to include access to trials and research as a core 
component of the MDT: ‘adequate resource provided 
for research nurses, clinical trials coordinators and data 
managers’ (p124). If a clinical service is developed to 
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Figure 3 Recommendations to improve recruitment to research. 1Low-represented also include, but are not limited to, the 
elderly, black and minority ethnic groups, people with the host language as a second language. NIHR CRN, National Institute for 
Health Clinical Research Network; TYA, teenage and young adult.
serve the unique needs of this population,26 then it is 
necessary to provide a similar research service, especially 
as the inclusion in research is a central recommendation 
and this is a target currently not being achieved.16 31 The 
importance of providing a population-specific research 
workforce was recognised from the inception of the CRN. 
Paediatric research resource exists across most hospitals 
in England providing cancer care. As more young people 
are diagnosed with cancer than children in England, it 
is not unreasonable to aspire to a TYA-specific research 
team, a team of healthcare professionals trained to work 
with young people who have the unique skill of acknowl-
edging young people’s vulnerability while being able to 
identify when it is appropriate to approach them about all 
the opportunities available to them with respect to their 
treatment and care. This has recently been recognised by 
the NIHR CRN, and their TYA cancer research strategy 
proposed a number of objectives to address the continued 
disparity in recruitment of young people to research38 to 
increase availability of studies for the TYA population:
 ► To establish a governance framework between TYA 
PTCs and designated centres and ensure equitable 
distribution of study sites.
 ► To establish a network-wide TYA research nurse/
worker infrastructure.
 ► To establish systems linking trial recruitment data to 
registration data to allow all forms of population-based 
research to be undertaken (including those that do 
not require consent).
Whether there are resources allocated to achieve these 
objectives is unclear at this stage, but there is for the first 
time a strategic plan to address many of the issues identi-
fied in our study.
The changes we propose are accompanied by resource 
implications on time, funding and staffing; however, 
we suggest these will be short-term costs, which will be 
nullified in the longer term with a legacy of an improved 
holistic interconnected multilevel system to aid recruit-
ment. This will ultimately lead to stronger evidence on 
which to base practice and policy.
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